Bioasis Technologies Stock Today
| BTI Stock | CAD 1.26 1.25 25,100% |
Performance20 of 100
| Odds Of DistressLess than 11
|
British Amer is selling for under 1.26 as of the 30th of November 2024; that is 25,100 percent increase since the beginning of the trading day. The stock's lowest day price was 1.25. British Amer has less than a 11 % chance of experiencing some financial distress in the next two years of operation and had a solid performance during the last 90 days. Equity ratings for biOasis Technologies are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 31st of October 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company was founded in 2007 and is based in New Haven, Connecticut. The company has 79.41 M outstanding shares of which 105.04 K shares are currently shorted by private and institutional investors with about 0.01 days to cover all short positions. More on biOasis Technologies
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
British Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. British Amer's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding British Amer or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman | Deborah Rathjen | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
British Amer's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to British Amer's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsBritish Amer can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand British Amer's financial leverage. It provides some insight into what part of British Amer's total assets is financed by creditors.
| |||||
biOasis Technologies (BTI) is traded on TSX Venture Exchange in Canada and employs 15 people. British Amer is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 397.07 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate British Amer's market, we take the total number of its shares issued and multiply it by British Amer's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. biOasis Technologies classifies itself under Biotechnology sector and is part of Health Care industry. The entity has 79.41 M outstanding shares of which 105.04 K shares are currently shorted by private and institutional investors with about 0.01 days to cover all short positions.
biOasis Technologies has accumulated about 2.68 M in cash with (3.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04.
Check British Amer Probability Of Bankruptcy
Ownership AllocationBritish Amer holds a total of 79.41 Million outstanding shares. Nearly 97.95 percent of British Amer outstanding shares are held by general public with 2.05 (percent) owned by insiders and only 0.0 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check British Ownership Details
biOasis Technologies Risk Profiles
Although British Amer's alpha and beta are two of the key measurements used to evaluate British Amer's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3516.05 | |||
| Standard Deviation | 6695.08 | |||
| Variance | 4.482409893E7 | |||
| Downside Variance | 2481.25 |
British Stock Against Markets
| BTI | 25,100 |
| Competition | Compare Correlations |
Be your own money manager
Our tools can tell you how much better you can do entering a position in British Amer without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Investing Opportunities Now
Investing OpportunitiesBuild portfolios using our predefined set of ideas and optimize them against your investing preferences |
| All Next | Launch Module |
British Amer Corporate Directors
| David Wurzer | Independent Director | Profile | |
| Mario Saltarelli | Non-Executive Director | Profile | |
| John Curran | Independent Director | Profile | |
| Aaron Elton | Director Marketing | Profile |
Additional Tools for British Stock Analysis
When running British Amer's price analysis, check to measure British Amer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy British Amer is operating at the current time. Most of British Amer's value examination focuses on studying past and present price action to predict the probability of British Amer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move British Amer's price. Additionally, you may evaluate how the addition of British Amer to your portfolios can decrease your overall portfolio volatility.